Protalix BioTherapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Protalix BioTherapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Protalix BioTherapeutics Inc Strategy Report
- Understand Protalix BioTherapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Protalix BioTherapeutics Inc (Protalix) is a biopharmaceutical company that is involved in the development and commercialization of recombinant therapeutic proteins. The company’s marketed product, Elelyso (taliglucerase alfa), is an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company also has pipeline product candidates that are intended for the treatment of cystic fibrosis, and NETs-related diseases. The company develops its proprietary pipeline of recombinant therapeutic proteins through its proprietary technology, ProCellEx plant cell-based protein expression system. It allows the company to rapidly develop a protein for clinical testing, compared to other protein platforms. Protalix is headquartered in New Jersey, the US.
Headquarters
United States of America
Address
2 University Plaza, Suite 100, Hackensack, New Jersey, 07601
Website
protalix.com
Telephone
1 201 6969345
No of Employees
208
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PLX (AFM)
Revenue (2022)
$65.5M
37.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
155.7%
(2022 vs 2021)
Market Cap*
$83.3M
Net Profit Margin (2022)
XYZ
140.5%
(2022 vs 2021)
* As of and is in US$
Protalix BioTherapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Marketed Product: | - |
| Elelyso (taliglucerase alfa) | ProCellEx |
| Pegunigalsidase Alfa (PRX-102) | Elelyso |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In May, the company’s PRX-102 (pegunigalsidase alfa) has received approval from the European Commission (EC) for the treatment of the Fabry disease. |
| 2021 | Contracts/Agreements | In February, the company entered into a partnership with SarcoMed USA Inc for alidornase alfa to treat human respiratory disease not limited to, sarcoidosis, pulmonary fibrosis. |
| 2020 | Contracts/Agreements | In October, the company entered into an agreement with Chiesi Global Rare Diseases to launch of expanded access program for Pegunigalsidase Alfa to treat fabry diseases in the US. |
Competitor Comparison
| Key Parameters | Protalix BioTherapeutics Inc | Johnson & Johnson | AbbVie Inc | Amicus Therapeutics Inc | Ligand Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Hackensack | New Brunswick | North Chicago | Philadelphia | Jupiter |
| State/Province | New Jersey | New Jersey | Illinois | Pennsylvania | Florida |
| No. of Employees | 208 | 131,900 | 50,000 | 517 | 58 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Eliot Richard Forster | Chairman | Executive Board | 2023 | - |
| Dror Bashan | Chief Executive Officer; Director; President | Executive Board | 2019 | 56 |
| Eyal Rubin | Chief Financial Officer; Senior Vice President | Senior Management | 2019 | 47 |
| Raul Chertkoff, M.D | Senior Advisor | Senior Management | 2022 | - |
| Yael Hayon, Ph.D. | Vice President - Research & Development | Senior Management | 2020 | 40 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer